This Month in Genetics  by Garber, Kathryn B.
EDITORS’ CORNER
This Month in Genetics
Kathryn B. Garber1,*Placebo-Controlled Trial of Substrate-Reduction
Therapy for Gaucher Disease type I
The mainstay treatment for many lysosomal-storage dis-
eases is enzyme-replacement therapy, an approach that re-
quires regular intravenous infusions. Although effective
for Gaucher disease, this lifelong treatment regimen is
burdensome on both practical and financial levels.
Another tactic for treating this disease is to reduce the
amount of substrate for the deficient enzyme by inhibiting
an enzyme upstream in the pathway. If efficacious, this
could alleviate some of the burden of treatment because
it can be given orally. The first FDA-approved substrate-
reduction therapy was miglustat, which is now a second-
line therapy for Gaucher disease type 1. A phase 3,
randomized, placebo-controlled trial of a more specific
and potent inhibitor of glucosylceramide synthase, eliglu-
stat, has now yielded promising results. In the 40 Gaucher
type 1 patients in the trial, many of whom were naive to
treatment, receipt of eliglustat for 9 months led to signifi-
cant reductions in spleen and liver volume and to increases
in platelet count. This treatment was the only one received
by patients during the trial, suggesting that it might pro-
vide benefits even without replacement of the defective
enzyme, at least over the short time of the study.
Mistry et al. (2015). JAMA 313, 695–706.
Pharmacogenetic Indicators of Toxicity in Children
Treated for Cancer
As our ability to treat certain childhood cancers improves,
we have more time to focus attention on the toxic side
effects of the treatments. Recently, two groups performed
genome-wide association studies (GWASs) of patients at
St. Jude’s Children’s Research Hospital to do just that.
Diouf et al. sought genetic variation that contributes to
vincristine-induced peripheral neuropathy in children be-
ing treated for leukemia. They found evidence that varia-
tion in CEP72 might increase the likelihood of this side
effect. This makes sense given that CEP72 encodes a cen-
trosomal protein critical for microtubule formation and
that vincristine acts by inhibiting microtubule formation.
About one-quarter of the children in the study overall suf-
fered from neuropathy, whereas more than half of those
homozygous for the CEP72 risk allele did. In their pharma-
cogenomics study, Xu et al. also found a plausible candi-
date gene, this time associated with cisplatin-induced
hearing loss in kids undergoing treatment for brain tu-1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Ammors. The gene they pulled out of their GWAS is ACYP2,
which encodes an acylphosphatase that is present in the
cochlea. These pharmacogenetic analyses provide a handle
for further understanding the toxic side effects of chemo-
therapy and, perhaps, might inform dosing of these treat-
ments in the future.
Diouf et al. (2015). JAMA 313, 815–823.
Xu et al. (2015). Nat. Genet. 47, 263–266.
A New View of Missense Variants
Understanding the potential impact of missense variation
is often less than straightforward. Mosca et al. have created
a new resource for the systematic mapping of disease-
related missense variants onto protein structures to under-
stand their impact on protein interactions. This resource,
dSysMap, has nearly 24,000 variants mapped onto more
than 2,000 proteins, and more can be uploaded. This
view of missense variation makes the complexity of inter-
pretation clear; two variants in the same protein but on
different interaction surfaces often lead to different pheno-
types. The authors also specifically present an overview of
gene mutations that cause Loeys-Dietz syndrome; these in
turn interact with gene products relevant to fibrodysplasia
ossificans progressiva and to juvenile polyposis syndrome.
Looking at the protein interactions illuminates how muta-
tions in the same network cause disparate phenotypes.
Mosca et al. (2015). Nat. Methods 12, 167–168.
Which Came First?
Years after chemotherapy or radiotherapy is used to treat
cancer, therapy-related acute myeloid leukemia (t-AML)
can develop. In about one-third of affected individuals,
TP53 mutations can be detected in these leukemias, but
it hasn’t been clear how these mutations become enriched.
To identify their origin, Wong et al. sequenced t-AMLs and
compared them to matched blood or bone marrow speci-
mens that were collected before the development of the
t-AML. In four out of seven pairs of samples, the TP53
mutation that was prevalent in the t-AML sample was
also present in the earlier sample (and some of these earlier
samples were collected even before chemotherapy was
initiated). As confirmed in mixed bone marrow cultures
treated with N-ethyl-N-nitrosurea, hematopoietic stem
cells that possess TP53 mutations have a competitive
advantage over those that do not. Thus, TP53 mutations
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normal aging might be selected if an individual is treated
for cancer and might ultimately contribute to the develop-
ment of t-AML.
Wong et al. (2015). Nature 518, 552–555.
When Mix-ups Are a Good Thing
The shuffling of genetic material during recombination
helps to ensure more diversity in our population. Without
it, the theory known as Muller’s ratchet predicts that disad-
vantageous mutations will accumulate over time because
there isn’t a way to bring in unadulterated haplotypes.
This idea has been studied with the Y chromosome, which
doesn’t recombine over most of its length, and has been
used for predicting the downfall of that chromosome. Hus-518 The American Journal of Human Genetics 96, 517–518, April 2, 2sin et al. have assessed the effects of recombination on a
much larger scale by using data from large population
studies, including CARTaGENE and the 1000 Genomes
Project. They report that, as predicted, exons located in
areas with low recombination rates have accumulated
more deleterious variation than those within regions that
are more likely to recombine. The regions of low recombi-
nation are enriched with genes involved in critical func-
tions such as DNA repair and cell-cycle regulation. There
is also an excess of human-disease-associated mutations
in these areas, suggesting a role for local recombination
rates in shaping the spectrum of human genetic disease.
Hussin et al. (2015). Nat. Genet. Published online February
16, 2015. http://dx.doi.org/10.1038/ng.3216.This Month in Our Sister JournalsMutations for Everyone
We are all thought to carry recessive deleterious mutations
in our genomes. Cultures that practice consanguinity
have a higher likelihood of developing autosomal-reces-
sive disorders because of the increased chance that two
members of a couple will carry the same mutation.
Through comparisons of consanguineous and non-
consanguineous relationships, researchers have tried to
estimate how many mutations we each carry, but these
analyses are somewhat confounded by between-group
socioeconomic differences that can also impact fitness.
To get around this confounder, Gao et al. used data from
the Hutterite group, a founder population that practicesa communal lifestyle and thus effectively equalizes socio-
economic conditions. A vast amount of information is
known about this group, including the original number
of founder individuals, a catalog of the severe genetic con-
ditions in the population, and extensive pedigree infor-
mation that connects thousands of Hutterite individuals.
Through use of this information, the authors calculated
that each of us carries an average of 0.58 severe auto-
somal-recessive alleles, which translates into a 1.8% in-
crease in the risk of lethal autosomal-recessive disorders
in couples who are first cousins.
Gao et al. (2015). Genetics. Published online February 18,
2015. http://dx.doi.org/10.1534/genetics.114.173351.015
